Vimseltinib

Vimseltinib is an inhibitor of colony stimulating factor 1 receptor (CSF1R, IC50 = 3.7 nM). It is selective for CSF1R over FMS-related tyrosine kinase 3 (FLT3), PDGFRalpha, PDGFRbeta, and KIT (IC50s = >3,300, 436, 2,300, and 476 nM, respectively). Vimseltinib inhibits the proliferation of M-NFS-60 leukemia cells (IC50 = 18 nM). It inhibits CSF1-induced CFS1R autophosphorylation in THP-1 cells (IC50 = 27 nM) and CSF1- and RANKL-induced osteoclast differentiation (IC50 = 9.3 nM).Formal Name: 3-methyl-2-[(1-methylethyl)amino]-5-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-4(3H)-pyrimidinone. CAS Number: 1628606-05-2. Synonyms: DCC-3014. Molecular Formula: C23H25N7O2. Formula Weight: 431.5. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: DMF: 10 mg/ml, DMSO: 10 mg/ml, Ethanol: 10 mg/ml. lambdamax: 264, 335 nm. SMILES: CN1C=C(C2=CC(OC3=CC=C(C4=CN=C(NC(C)C)N(C4=O)C)N=C3C)=CC=N2)C=N1. InChi Code: InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27). InChi Key: TVGAHWWPABTBCX-UHFFFAOYSA-N.